{
    "code": 0,
    "data": [
        {
            "sym": "BLISSGVS",
            "disp": "Bliss GVS Pharma",
            "bse_code": 506197,
            "isin": "INE416D01022",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of Board Meeting Held On Tuesday February 10 2026",
            "news_body": "Please find enclosed herewith the Outcome of the Board Meeting held on February 10 2026.",
            "news_id": "8dbcd76c-f9dd-451d-a5cc-0c667a273424",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=26cda15c-8e7d-456e-96e9-59883a60df9a.pdf",
            "news_date": "2026-02-10 15:22:39",
            "seo": "bliss-gvs-pharma-ltd",
            "ltp": 214.22,
            "ch": 6.150000000000006,
            "pch": 2.9557360503676673,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 19265,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BLISSGVS",
            "disp": "Bliss GVS Pharma",
            "bse_code": 506197,
            "isin": "INE416D01022",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Yearly Ended September 30 2025",
            "news_body": "Please find attached the unaudited standalone and consolidated financial results for the quarter and half yearly ended September 30 2025.",
            "news_id": "3612f58c-cebe-4db1-96ae-d084ac8f5ebb",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d9fde745-9e3e-4712-869a-bc028b3247ac.pdf",
            "news_date": "2025-11-06 20:54:18",
            "seo": "bliss-gvs-pharma-ltd",
            "ltp": 214.22,
            "ch": 6.150000000000006,
            "pch": 2.9557360503676673,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 19265,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BLISSGVS",
            "disp": "Bliss GVS Pharma",
            "bse_code": 506197,
            "isin": "INE416D01022",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of Board Meeting Held On Tuesday July 29 2025",
            "news_body": "We wish to inform you that the Board of Directors at its meeting held today i.e. Tuesday July 29 2025 has considered and approved the unaudited standalone and consolidated financial results for the quarter ended June 30 2025.",
            "news_id": "8ed32e93-1f66-458b-afaa-fa1212ba6573",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a9d22cd4-35e4-434a-8657-51f2cb5e952a.pdf",
            "news_date": "2025-07-29 18:25:07",
            "seo": "bliss-gvs-pharma-ltd",
            "ltp": 214.22,
            "ch": 6.150000000000006,
            "pch": 2.9557360503676673,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 19265,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BLISSGVS",
            "disp": "Bliss GVS Pharma",
            "bse_code": 506197,
            "isin": "INE416D01022",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Nine Months Ended December 31 2024",
            "news_body": "Please find attached the outcome of Board Meeting held on Tuesday January 28 2025.",
            "news_id": "be557f40-b9b9-4b40-a808-398a4395961f",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7d8e8259-1b09-4cad-9377-3237fcfc95df.pdf",
            "news_date": "2025-01-28 19:32:34",
            "seo": "bliss-gvs-pharma-ltd",
            "ltp": 214.22,
            "ch": 6.150000000000006,
            "pch": 2.9557360503676673,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 19265,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BLISSGVS",
            "disp": "Bliss GVS Pharma",
            "bse_code": 506197,
            "isin": "INE416D01022",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30, 2024",
            "news_body": "Please find attached herewith the Outome of Board Meeting held on today i.e. July 24, 2024 for approval of Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2024.",
            "news_id": "0d306e2d-5854-4728-a22a-107c2d18228f",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a796ae32-e72c-4a45-affa-ba13fd874545.pdf",
            "news_date": "2024-07-24 14:17:03",
            "seo": "bliss-gvs-pharma-ltd",
            "ltp": 214.22,
            "ch": 6.150000000000006,
            "pch": 2.9557360503676673,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 19265,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BLISSGVS",
            "disp": "Bliss GVS Pharma",
            "bse_code": 506197,
            "isin": "INE416D01022",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Year Ended March 31, 2024",
            "news_body": "Please find attached herewith Outcome of the Board Meeting held on May 02, 2024.",
            "news_id": "3367d786-051f-4aff-90b3-d97f643d5436",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c7ec929e-baca-4fa9-887e-24a463f7d69b.pdf",
            "news_date": "2024-05-02 21:56:47",
            "seo": "bliss-gvs-pharma-ltd",
            "ltp": 214.22,
            "ch": 6.150000000000006,
            "pch": 2.9557360503676673,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 19265,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BLISSGVS",
            "disp": "Bliss GVS Pharma",
            "bse_code": 506197,
            "isin": "INE416D01022",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Standalone And Consolidated Financial Results For The Quarter And Nine Months Ended December 31, 2023",
            "news_body": "Enclosed herewith the outcome of board meeting held on January 23, 2024",
            "news_id": "8aaa8bf0-d76c-4aec-87e6-2d549dec80ee",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9e92191f-a411-4e93-a37b-48be6876ac0d.pdf",
            "news_date": "2024-01-23 23:36:05",
            "seo": "bliss-gvs-pharma-ltd",
            "ltp": 214.22,
            "ch": 6.150000000000006,
            "pch": 2.9557360503676673,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 19265,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BLISSGVS",
            "disp": "Bliss GVS Pharma",
            "bse_code": 506197,
            "isin": "INE416D01022",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2023",
            "news_body": "We would like to inform you that the Board Meeting of the Company was held today i.e. Wednesday, November 01, 2023, at the registered office of the Company. In pursuant to Regulation 30 and Regulation 33 read with Schedule III of SEBI Listing Regulations. Enclosed herewith Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2023 along with Limited Review Report.",
            "news_id": "9624be38-88ee-4ede-beee-91880931f113",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b48acac1-1434-459e-9f49-dd5f6cb99b74.pdf",
            "news_date": "2023-11-01 20:35:55",
            "seo": "bliss-gvs-pharma-ltd",
            "ltp": 214.22,
            "ch": 6.150000000000006,
            "pch": 2.9557360503676673,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 19265,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BLISSGVS",
            "disp": "Bliss GVS Pharma",
            "bse_code": 506197,
            "isin": "INE416D01022",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Year Ended March 31, 2023",
            "news_body": "We would like to inform you that, the Board Meeting of the Company was held today i.e. Thursday, May 11, 2023 at the registered office of the Company. In pursuant to                 Regulation 30 and Regulation 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board has considered and approved the matters amongst others as attached.",
            "news_id": "d6241d13-0e61-41ba-bd57-2c11d73e80f4",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e10fa2cc-0606-422d-927e-a8adc7d02235.pdf",
            "news_date": "2023-05-11 22:48:54",
            "seo": "bliss-gvs-pharma-ltd",
            "ltp": 214.22,
            "ch": 6.150000000000006,
            "pch": 2.9557360503676673,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 19265,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BLISSGVS",
            "disp": "Bliss GVS Pharma",
            "bse_code": 506197,
            "isin": "INE416D01022",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome For Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Nine Months Ended December 31, 2022",
            "news_body": "We would like to inform you that, Board Meeting of the Company was held today i.e. Tuesday, January 24, 2023 at the registered office of the Company. In pursuant to  Regulation 30 and 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the Board has considered and approved the following matter amongst others:<BR> <BR> i. The Unaudited Standalone and Consolidated Financial Results of the company for the quarter and nine months ended December 31, 2022. A copy of unaudited financial results along with the Limited Review Report of the Auditors of the Company are enclosed herewith as 'Annexure - I'.<BR> <BR> The meeting of the Board of Directors commenced at 05:30 p.m. and concluded at 08:55 p.m.<BR>",
            "news_id": "3162a322-e7fa-4612-98e6-bd1ce27b9100",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a1b06609-8829-4431-9698-a069fa4bc4ed.pdf",
            "news_date": "2023-01-24 21:08:51",
            "seo": "bliss-gvs-pharma-ltd",
            "ltp": 214.22,
            "ch": 6.150000000000006,
            "pch": 2.9557360503676673,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 19265,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BLISSGVS",
            "disp": "Bliss GVS Pharma",
            "bse_code": 506197,
            "isin": "INE416D01022",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Clarification W.R.T Submission Of Outcome Of The Board Meeting Held On Monday, November 07, 2022",
            "news_body": "Please find the attachment.",
            "news_id": "ad5096b5-a171-4d30-9ce5-e801c3f86b6f",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2e0b810d-a3eb-4f96-a336-55045bf4855a.pdf",
            "news_date": "2022-11-23 18:18:24",
            "seo": "bliss-gvs-pharma-ltd",
            "ltp": 214.22,
            "ch": 6.150000000000006,
            "pch": 2.9557360503676673,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 19265,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BLISSGVS",
            "disp": "Bliss GVS Pharma",
            "bse_code": 506197,
            "isin": "INE416D01022",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Disclosure Of Related Party Transactions Under Regulation 23(9) Of SEBI (LODR) Regulations, 2015",
            "news_body": "Pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, please find enclosed herewith  a disclosure of Related Party Transactions in the specified format for the half year ended  September 30, 2022.Kindly take the same on your record.",
            "news_id": "58f1bbe1-5bff-45d2-b095-b306be024ec2",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=23a4d578-d5bc-44c4-8c03-d82b89d01f9e.pdf",
            "news_date": "2022-11-21 21:44:54",
            "seo": "bliss-gvs-pharma-ltd",
            "ltp": 214.22,
            "ch": 6.150000000000006,
            "pch": 2.9557360503676673,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 19265,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BLISSGVS",
            "disp": "Bliss GVS Pharma",
            "bse_code": 506197,
            "isin": "INE416D01022",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30, 2022",
            "news_body": "We would like to inform you that, Board Meeting of the Company was held today i.e. Monday, November 07, 2022 at the registered office of the Company. In pursuant to Regulation 30 and 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the Board has considered and approved the following matter amongst others:<BR> <BR> 1. The Unaudited Standalone and Consolidated Financial Results of the company for the quarter and half year ended September 30, 2022. A copy of unaudited financial results along with the Limited Review Report of the Auditors of the Company are enclosed herewith as 'Annexure - I'.<BR> <BR> The meeting of the Board of Directors commenced at 05:30 p.m. and concluded at 07:45 p.m.<BR> <BR>",
            "news_id": "affec892-d069-4bf5-8316-619f6e943130",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8ec4f38f-a5af-4fad-8533-b9bf0a328c48.pdf",
            "news_date": "2022-11-07 20:05:17",
            "seo": "bliss-gvs-pharma-ltd",
            "ltp": 214.22,
            "ch": 6.150000000000006,
            "pch": 2.9557360503676673,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 19265,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BLISSGVS",
            "disp": "Bliss GVS Pharma",
            "bse_code": 506197,
            "isin": "INE416D01022",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting Held On Wednesday, August 03, 2022",
            "news_body": "We would like to inform you that, Board Meeting of the Company was held today i.e. Wednesday, August 03, 2022 at the registered office of the Company. In pursuant to Regulation 30 and 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the Board has considered and approved the following matter amongst others:<BR> 1.The Unaudited Standalone and Consolidated Financial Results of the company for the quarter ended June 30, 2022. A copy of unaudited financial results along with the Limited Review Report of the Auditors of the Company are enclosed herewith as 'Annexure - I'.",
            "news_id": "20db96a6-d606-49e7-9f8b-0e5ea20016c2",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=31882a7e-ef40-4737-b588-cf65cfc9e739.pdf",
            "news_date": "2022-08-03 20:46:54",
            "seo": "bliss-gvs-pharma-ltd",
            "ltp": 214.22,
            "ch": 6.150000000000006,
            "pch": 2.9557360503676673,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 19265,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BLISSGVS",
            "disp": "Bliss GVS Pharma",
            "bse_code": 506197,
            "isin": "INE416D01022",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of Board Meeting Held On Saturday, April 30, 2022",
            "news_body": "1.The Audited standalone and consolidated financial results of the Company for the quarter and year ended March 31, 2022 <BR> 2. Recommended Final dividend of 50% i.e. 0.50 paisa per equity share having face value of  Rs.1/- each for the financial year ended March 31, 2022<BR> 3. Re-appointment of M/s. Kalyaniwalla Mistry & LLP, Chartered Accountants (Firm Registration No. 104607W/W100166), Peer Reviewed Firm as the Statutory Auditors <BR> 4. Re-appointment of M/s. BDO India LLP, Chartered Accountant having LLP registration no. AAB-7880 as Internal Auditor of the Company for the financial year 2022-23<BR> 5. Re-appointment of M/s. AVS & Associates, Practicing Company Secretaries, Peer Reviewed Firm as Secretarial Auditor of the Company for the financial year 2022-23<BR> 6. 37th AGM of the Company for the Financial Year 2021-2022 has been scheduled to be held on Tuesday, June 28, 2022 at 11:00 a.m. through Video Conferencing ('VC') / Other Audio Visual Means ('OAVM') facility",
            "news_id": "09401cbc-bb61-4129-a57a-c7accdca3888",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2433b646-35aa-4163-accc-6bf38e4c9458.pdf",
            "news_date": "2022-04-30 20:46:31",
            "seo": "bliss-gvs-pharma-ltd",
            "ltp": 214.22,
            "ch": 6.150000000000006,
            "pch": 2.9557360503676673,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 19265,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BLISSGVS",
            "disp": "Bliss GVS Pharma",
            "bse_code": 506197,
            "isin": "INE416D01022",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Standalone And Consolidated Financial Results For The Quarter And Nine Months Ended December 31, 2021",
            "news_body": "We would like to inform you that, Board Meeting of the Company was held today                                    i.e. Saturday, January 29, 2022 at the registered office of the Company. In pursuant to                    Regulation 30 and 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the Board has considered and approved the following matter amongst others:<BR> 1. The Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2021. A copy of unaudited financial results along with the Limited Review Report of the Auditors of the Company are enclosed herewith as 'Annexure - I'.",
            "news_id": "a9025b92-711e-46c2-a92c-81843e9ffdfc",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9fe04feb-8175-4003-8cd4-32ec0b73e3bb.pdf",
            "news_date": "2022-01-29 21:13:44",
            "seo": "bliss-gvs-pharma-ltd",
            "ltp": 214.22,
            "ch": 6.150000000000006,
            "pch": 2.9557360503676673,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 19265,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BLISSGVS",
            "disp": "Bliss GVS Pharma",
            "bse_code": 506197,
            "isin": "INE416D01022",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for  Unaudited Standalone And Consolidated Financial Result For The Quarter And Half Yearly Ended September 30, 2021",
            "news_body": "We would like to inform you that, Board Meeting of the Company was held today  i.e. Saturday, October 30, 2021 at the registered office of the Company. In pursuant to Regulation 30 and 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the Board has considered and approved the matters as per attachment.",
            "news_id": "c2a6e2a5-4c5b-45d7-8013-81be0ef8d11e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1a5aa26e-f372-42dc-a796-80a5a1e2ee78.pdf",
            "news_date": "2021-10-30 17:51:51",
            "seo": "bliss-gvs-pharma-ltd",
            "ltp": 214.22,
            "ch": 6.150000000000006,
            "pch": 2.9557360503676673,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 19265,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BLISSGVS",
            "disp": "Bliss GVS Pharma",
            "bse_code": 506197,
            "isin": "INE416D01022",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Standalone And Consolidated Financial Result For The Quarter Ended June 30, 2021",
            "news_body": "We would like to inform you that, Board Meeting of the Company was held today i.e. Saturday, July 31, 2021 at the registered office of the Company. In pursuant to Regulation 30 and 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the Board has considered and approved the matters as per attachment.",
            "news_id": "fb241702-ab6a-4e11-8c77-de9c7ee242fd",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cae3efae-ee87-49ae-bbd9-26525c741402.pdf",
            "news_date": "2021-07-31 17:44:41",
            "seo": "bliss-gvs-pharma-ltd",
            "ltp": 214.22,
            "ch": 6.150000000000006,
            "pch": 2.9557360503676673,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 19265,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BLISSGVS",
            "disp": "Bliss GVS Pharma",
            "bse_code": 506197,
            "isin": "INE416D01022",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Year Ended March 31, 2021",
            "news_body": "1. Audited standalone and consolidated financial results of the Company for the quarter and year ended March 31, 2021 along with the audit report with declaration of unmodified opinion <BR> <BR> 2. Recommended Final dividend of 50% i.e. 0.50 paisa per equity share on face value of Rs. 1/- each for the financial year ended March 31, 2021<BR> <BR> 3.Re-appointment of M/s. BDO India LLP, Chartered Accountant having LLP registration no. AAB-7880 as Internal Auditor<BR> <BR> 4. Issue & Allotment of 2,10,500 Equity Shares of face value of Rs. 1 each of the Company under 'Bliss GVS Pharma Limited-Employee Stock Option Plan 2019' <BR> <BR> 5.Re-appointment of Mr. Santosh Laxman Parab (DIN:01622988), as an Non-Executive Independent Director of the Company<BR> <BR> 6. Resignation of Mr. S N Kamath from the position of Managing Director <BR> <BR> 7. Appointment of Mr. Gagan Harsh Sharma (DIN:07939421) as Managing Director of the Company<BR> <BR> 8. Reconstitution  of Committees",
            "news_id": "7fd850ad-07f9-405e-8514-9682d7ddf63d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a785be82-b2bc-4c19-861d-5caa956dd20a.pdf",
            "news_date": "2021-05-11 19:41:15",
            "seo": "bliss-gvs-pharma-ltd",
            "ltp": 214.22,
            "ch": 6.150000000000006,
            "pch": 2.9557360503676673,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 19265,
            "exch": "NSE",
            "seg": "E"
        }
    ],
    "remarks": ""
}